Abstract
Recursion is again shaking up its pipeline, announcing Thursday it will stop work on a group of preclinical and early-stage cancer drugs to focus its resources elsewhere. The decision is the latest course correction for the artificial intelligence-focused biotechnology company.
Key Data
-
Publication Date09 May 2025
-
Primary AuthorBen Fidler
-
SourceBioPharma Dive
-
LanguageEnglish
Click below to visit original source: